Archives

Biomedicines, Vol. 13, Pages 3079: Added Value to GLP-1 Receptor Agonist: Intermittent Fasting and Lifestyle Modification to Improve Therapeutic Effects and Outcomes

Biomedicines, Vol. 13, Pages 3079: Added Value to GLP-1 Receptor Agonist: Intermittent Fasting and Lifestyle Modification to Improve Therapeutic Effects and Outcomes Biomedicines doi: 10.3390/biomedicines13123079 Authors: Dragos Cozma Cristina Văcărescu Claudiu Stoicescu Obesity remains a major global health challenge, with glucagon-like peptide-1 receptor agonists (GLP-1RAs) providing substantial yet sensitive benefits in weight reduction, glycemic control, […]

IJMS, Vol. 26, Pages 12003: Mollugin: A Comprehensive Review of Its Multifaceted Pharmacological Properties and Therapeutic Potential

IJMS, Vol. 26, Pages 12003: Mollugin: A Comprehensive Review of Its Multifaceted Pharmacological Properties and Therapeutic Potential International Journal of Molecular Sciences doi: 10.3390/ijms262412003 Authors: Sandra Ross Olakkengil Shajan Bushra Zia Charu Sharma Sandeep B. Subramanya Shreesh Ojha The substantial interest in plant-based drugs or plant-derived phytocompounds drives researchers to conduct comprehensive investigations on their […]

Effectiveness of Pre‐Transplant Dual GLP‐1 Receptor Agonist and SGLT2 Inhibitor Therapy on All‐Cause Mortality in Organ Transplantation Candidates with Obesity and Type 2 Diabetes: a Target‐Trial Emulation

This target trial emulation in solid organ transplant candidates with obesity and type 2 diabetes evaluates whether pre-transplant dual therapy with GLP-1 receptor agonists plus SGLT2 inhibitors is associated with post-transplant mortality and kidney graft outcomes compared with monotherapy or usual care, using multinational electronic health records and extensive sensitivity analyses. Abstract Evidence on pre-transplant […]

Peripheral CB1R inhibition modulates food intake and metabolic efficiency in obesity independently of the gut-brain vagal axis

Obesity arises from profound disruptions in neuroendocrine communication and impaired central regulation of energy homeostasis. The endocannabinoid system (ECS), through cannabinoid type-1 receptors (CB1Rs), is a key modulator of feeding, metabolism, and gut-brain signaling. While global CB1R blockade improves metabolic control, its clinical translation has been limited by adverse neuropsychiatric effects, underscoring the therapeutic potential […]

UBS Outlines Three Reasons For Sober Revolution Crushing Spirits Market

UBS Outlines Three Reasons For Sober Revolution Crushing Spirits Market There are just thirteen days until Christmas. Friends and family are gathering; eggnog, spiked with bourbon, dark or spiced rum, or cognac, is flowing, and Christmas music fills homes, restaurants, and bars, blaring from speakers tuned to holiday playlists. But this Christmas season, like the […]

New Weight-Loss Pills Could Arrive Sooner Than We Think

Yevgen_Rychko / Getty Images Millions of Americans have successfully lost weight with semaglutides, the game-changing class of drugs that includes Ozempic, Mounjaro, and Wegovy. Still, many others are holding out for GLP-1 medication to arrive in pill form—and they may not have to wait much longer. Orforglipron, a GLP-1 agonist administered as a pill, is […]

Ozempic explained: How this hormone-based drug actually works

Introducing Ozempic, a groundbreaking GLP-1 agonist now making waves in India! This innovative treatment emulates a natural gut hormone, providing a new approach for managing type 2 diabetes and obesity. By enhancing insulin production and lowering glucagon levels, it assists in stabilizing blood sugar. Plus, it helps you feel satisfied longer by slowing down digestion […]

Eli Lilly’s Next-Generation Obesity Drug Secures First Phase III Win

Shares of Eli Lilly LLY rose nearly 2% on Thursday after the company announced that a late-stage study evaluating its experimental once-weekly weight-loss drug, retatrutide, met all primary and key secondary endpoints. This study, called TRIUMPH-4, evaluated two doses (9 mg and 12 mg) of the drug for 68 weeks against placebo in adults with obesity […]